Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

Journal:

Nature Medicine

Published:

2026-04-20

DOI:

10.1038/s41591-026-04365-y

Affiliations:

9

Authors:

42

Go to article

Institutions	Authors	Share
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	31.500000 31.500000 31.500000 31.500000	0.75
Johnson & Johnson, United States of America (USA)	7.000000	0.17
Brigham and Women's Hospital (BWH), United States of America (USA)	1.500000	0.04
Janssen Research & Development, LLC (J&J PRD), United States of America (USA)	1.000000	0.02
Institute of Biomedical Research of Salamanca (IBSAL), Spain	1.000000	0.02

Interested in Oncology and Carcinogenesis?